Vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small cell lung cancer

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Gasti G, Hermann T, Steurer M, et al. Angiogenesis as a target for tumor treatment. Oncology. 1997;54(3):177–184.
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–1027.
   PubMed Web of Science ®Google Scholar
• Betsholtz C, Karlsson L, Lindahl P. Developmental roles of platelet-derived growth factors. Bioessays. 2001;23(6):494–507.
   PubMed Web of Science ®Google Scholar
• Dong J, Grunstein J, Tejada M, et al. VEGF-null cells require PDGFR alpha signalling mediated stromal fibroblast recruitment for tumorigenesis. Embo J. 2004;23(14):2800–2810.
   PubMed Web of Science ®Google Scholar
• Ahmad I, Iwata T, Leung HY. Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta. 2012;1823(4):850–860.
   PubMed Web of Science ®Google Scholar
• Gaur P, Bose D, Samuel S, et al. Targeting tumor angiogenesis. Semin Oncol. 2009;36(Suppl 1):S12–S19.
   PubMedGoogle Scholar
• Rajabi M, Mousa SA. The role of angiogenesis in cancer treatment. Biomedicines. 2017;5(2):34.
   PubMed Web of Science ®Google Scholar
• Ribatti D, Nico B, Crivellato E, et al. The history of the angiogenic switch concept. Leukemia. 2007;21:44–52.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676.
   PubMed Web of Science ®Google Scholar
• Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in psychology and medicine. Genes Dev. 2008;22(10):1276–1312.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307.
   PubMed Web of Science ®Google Scholar
• O’Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small cell lung cancer. Br J Cancer. 2000;82(8):1427–1432.
   PubMed Web of Science ®Google Scholar
• Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis. 2010;13:1–14.
   PubMed Web of Science ®Google Scholar
• Liu Q, Yu S, Zhao W, et al. EGFR-TKIs resistance via EGFR independent signaling pathways. Mol Cancer. 2018;17:53.
   PubMed Web of Science ®Google Scholar
• Cowan-Jacob SW. Structural biology of protein tyrosine kinases. Cell Mol Life Sci. 2006;63:2608–2625.
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211–225.
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–1027.
   PubMed Web of Science ®Google Scholar
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8:235–253.
   PubMed Web of Science ®Google Scholar
• Regad T. Targeting RTK Signaling pathways in cancer. Cancers (Basel). 2015;7(3):1758–1784.
   PubMed Web of Science ®Google Scholar
• Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018;17:353–377.
   PubMed Web of Science ®Google Scholar
• Niland S, Eble JA. Neuropilins in the context of tumor vasculature. Int J Mol Sci. 2019;20(3):E639.
   PubMed Web of Science ®Google Scholar
• Koch S, Tugues S, Li X, et al. Signal transduction by vascular endothelial growth factor receptors. Biochem J. 2011;437(2):169–183.
   PubMed Web of Science ®Google Scholar
• Wang J, Huang Y, Zhang J, et al. NRP-2 in tumor lymphangiogenesis and lymphatic metastasis. Cancer Lett. 2018;418:176–184.
   PubMed Web of Science ®Google Scholar
• Gemmill RM, Nasarre P, Nair-Menon J, et al. The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer. Sci Signal. 2017;10(462):eaag0528.
   PubMed Web of Science ®Google Scholar
• Lambrechts D, Lenz HJ, de Haas S, et al. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol. 2013;31(9):1219–1230.
   PubMed Web of Science ®Google Scholar
• Baumgarten P, Blank AE, Franz K, et al. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, −2, and −3 and co-receptors neuropilin-1 and −2 does not predict bevacizumab response in human astrocytomas. Neuro Oncol. 2016;18(2):173–183.
   PubMed Web of Science ®Google Scholar
• Bais C, Mueller B, Brady MF, et al. Tumor microvessel density as a potential predictive marker for bevacizumab benefit: GOG-0218 biomarker analyses. J Natl Cancer Inst. 2017;109:11.
   Google Scholar
• Weekes CD, Beeram M, Tolcher AW, et al. A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs. 2014;32(4):653–660.
   PubMed Web of Science ®Google Scholar
• Patnaik A, LoRusso PM, Messersmith WA, et al. A phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014;73(5):951–960.
   PubMed Web of Science ®Google Scholar
• Jarvis A, Allerston CK, Jia H, et al. Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem. 2010;53(5):2215–2226.
   PubMed Web of Science ®Google Scholar
• Binétruy-Tournaire R, Demangel C, Malavaud B, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. Embo J. 2000;19(7):1525–1533.
   PubMed Web of Science ®Google Scholar
• Barr MP, Byrne AM, Duffy AM, et al. A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells. Br J Cancer. 2005;92(2):328–333.
   PubMed Web of Science ®Google Scholar
• Sidman RL, Li J, Lawrence M, et al. The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease. Sci Transl Med. 2015;7(309):309ra165.
   PubMed Web of Science ®Google Scholar
• Hong TM, Chen YL, Wu YY, et al. Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer Res. 2007;13(16):4759–4768.
   PubMed Web of Science ®Google Scholar
• Jia H, Aqil R, Cheng L, et al. N-terminal modification of VEGF-A C terminus-derived peptides delineates structural features involved in neuropilin-1 binding and functional activity. Chembiochem. 2014;15(8):1161–1170.
   PubMed Web of Science ®Google Scholar
• Powell J, Mota F, Steadman D, et al. Small molecule neuropilin-1 antagonists combine antiangiogenic and antitumor activity with immune modulation through reduction of transforming growth factor beta (TGFβ) production in regulatory T-cells. J Med Chem. 2018;61(9):4135–4154.
   PubMed Web of Science ®Google Scholar
• Zhang L, Parry GC, Levin EG. Inhibition of tumor cell migration by LD22-4, an N-terminal fragment of 24-kDa FGF2, is mediated by Neuropilin 1. Cancer Res. 2013;73(11):3316–3325.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Bae J, Shin TH, et al. Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis. J Control Release. 2015;216:56–68.
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68(12):4774–4782.
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small cell lung cancer (LUME-lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–155.
   PubMed Web of Science ®Google Scholar
• Novello S, Kaiser R, Mellemgaard A, et al. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. Eur J Cancer. 2015;51(3):317–326.
   PubMed Web of Science ®Google Scholar
• Hanna NH, Kaiser R, Sullivan RN, et al. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): a randomized, double-blind, phase III trial. Lung Cancer. 2016;102:65–73.
   PubMed Web of Science ®Google Scholar
• Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109:1207–1219.
   PubMed Web of Science ®Google Scholar
• Taurin S, Yang CH, Reyes M, et al. Treatment of endometrial cancer cells with a new small tyrosine kinase inhibitor targeting mutated fibroblast growth factor receptor-2. Cancer Res. 2017;77(Suppl 13):3244.
   PubMedGoogle Scholar
• Lin B, Song X, Yang D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene. 2018;654:77–86.
   PubMed Web of Science ®Google Scholar
• Chia Tai Tianqing Pharmaceutical. Anlotinib hydrochloride capsules. 2018. cited 2019 Jul 29]. Available from: https://www.cttq.com.
   Google Scholar
• Taurin S, Yang CH, Reyes M, et al. Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model. Int J Gynecol Cancer. 2018;28(1):152–160.
   PubMed Web of Science ®Google Scholar
• Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9(1):105.
   PubMedGoogle Scholar
• Han B, Li K, Zhao Y, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118:654–661.
   PubMed Web of Science ®Google Scholar
• Han B, Li K, Wang Q, et al. Third-line treatment: a randomized, double-blind, placebo-controlled phase III ALTER-0303 study – efficacy and safety of anlotinib treatment in patients with refractory advanced NSCLC. J Clin Oncol. 2017;35(Suppl 15):9053.
   Google Scholar
• Li K, Han B, Wang Q, et al. OS outcomes to anlotinib in patients (pts) with refractory NSCLC of both wild-type (WT) and mutant EGFR. J Clin Oncol. 2018;36(Suppl 15):e21013.
   Google Scholar
• Shi J, Han B, Li K, et al. Subgroup analysis of elderly patients (pts) in ALTER0303: anlotinib hydrochloride as 3rd-line and further line treatment in refractory advanced NSCLC pts from a randomized, double-blind, placebo-controlled phase III ALTER0303 trial. J Clin Oncol. 2018;36(Suppl 15):e21181.
   Google Scholar
• Cheng Y, Han B, Li K, et al. Subgroup analysis of histology in ALTER0303: anlotinib hydrochloride as 3rd line and further line treatment in refractory advanced NSCLC patients (pts). J Clin Oncol. 2018;36(Suppl 15):9080.
   Web of Science ®Google Scholar
• Han B, Li K, Wang Q, et al. Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2017;18(Suppl 1):S3.
   PubMedGoogle Scholar
• Liu Z, Wang J, Meng Z, et al. Analysis on ALTER0303 trial: aCECs level may correlate with metastases burden and predict PFS of anlotinib in advanced NSCLC. J Thorac Oncol. 2017;12:S2234–5.
   Web of Science ®Google Scholar
• Han B, Zhao Y, Li K, et al. P3. Blood samples NGS for baseline molecular signature of anlotinib treated advanced NSCLC patients in ALTER0303 trial. J Thorac Oncol. 2017;12:S2279.
   Web of Science ®Google Scholar
• Wakelee HA, Lee JW, Hanna NH, et al. A double-blind randomized discontinuation phase II study of sorafenib (BAY 43-9006) in previously treated non-small cell lung cancer patients: eastern cooperative oncology group study E2501. J Thorac Oncol. 2012;7:1574–1582.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Burris HA 3rd, Greco FA, et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small cell lung cancer. J Clin Oncol. 2011;29:2582–2589.
   PubMed Web of Science ®Google Scholar
• Molina JR, Dy GK, Foster NR, et al. A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study. J Clin Oncol. 2011;29(Suppl 15):7513.
   Web of Science ®Google Scholar
• Paz-Ares L, Hirsh V, Zhang L, et al. Monotherapy administration of sorafenib in patients with non-small cell lung cancer (MISSION) trial. J Thorac Oncol. 2015;10:1745–1753.
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, Biesma B, Heigener D, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small cell lung cancer. J Clin Oncol. 2012;30:3084–3092.
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small cell lung cancer. J Clin Oncol. 2010;28:1835–1842.
   PubMed Web of Science ®Google Scholar
• Nassif E, Thibault C, Vano Y, et al. Sunitinib in kidney cancer: 10 years of experience and development. Expert Rev Anticancer Ther. 2017;17(2):129–142.
   PubMed Web of Science ®Google Scholar
• Heist RS, Wang X, Hodgson L, et al. A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9:214–221.
   PubMed Web of Science ®Google Scholar
• Baggstrom MQ, Socinski MA, Wang XF, et al. Maintenance sunitinib following initial platinum-based combination chemotherapy in advanced-stage IIIB/IV non-small cell lung cancer: a randomized, double-blind, placebo-controlled phase III study-CALGB 30607. J Thorac Oncol. 2017;12(5):843–849.
   PubMed Web of Science ®Google Scholar
• Groen HJ, Socinski MA, Grossi F, et al. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). Ann Oncol. 2013;24:2382–2389.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small cell lung cancer: a phase III trial. J Clin Oncol. 2012;30:2070–2078.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010;11:619–626.
   PubMed Web of Science ®Google Scholar
• de Boer RH, Arrieta O, Yang CH, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2011;29:1067–1074.
   PubMed Web of Science ®Google Scholar
• Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small cell lung cancer. J Clin Oncol. 2011;29:1059–1066.
   PubMed Web of Science ®Google Scholar
• Lee JS, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol. 2012;30:1114–1121.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist. 2013;18(7):865–875.
   PubMed Web of Science ®Google Scholar
• Yoh K, Seto T, Satouchi M, et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med. 2017;5(1):42–50.
   PubMed Web of Science ®Google Scholar
• Lee SH, Lee JK, Ahn MJ, et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Ann Oncol. 2017;28(2):292–297.
   PubMed Web of Science ®Google Scholar
• Heymach J, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:5407–5415.
   PubMed Web of Science ®Google Scholar
• Gridelli C, Novello S, Zilembo N, et al. Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small cell lung cancer in elderly patients. J Thorac Oncol. 2014;9(5):733–737.
   PubMed Web of Science ®Google Scholar
• Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102:1374–1380.
   PubMed Web of Science ®Google Scholar
• Ding J, Chen X, Gao Z, et al. Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans. Drug Metab Dispos. 2013;41:1195–1210.
   PubMed Web of Science ®Google Scholar
• Mi YJ, Liang YJ, Huang HB, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010;70:7981–7991.
   PubMed Web of Science ®Google Scholar
• Zhang L, Shi MQ, Huang C, et al. A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens. J Clin Oncol. 2012;30(Suppl 15):7548.
   Web of Science ®Google Scholar
• Song Z, Yu X, Lou G, et al. Salvage treatment with apatinib for advanced non-small cell lung cancer. Onco Targets Ther. 2017;10:1821–1825.
   PubMed Web of Science ®Google Scholar
• Liu Z, Ou W, Li N, et al. Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy. Thorac Cancer. 2018;9(10):1285–1290.
   PubMed Web of Science ®Google Scholar
• Wu D, Liang L, Nie L, et al. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: apatinib treatment in nonsquamous NSCLC. Asia Pac J Clin Oncol. 2018;14(6):446–452.
   PubMed Web of Science ®Google Scholar
• Hellerstedt BA, Edelman G, Vogelzang NJ, et al. Activity of cabozantinib (XL184) in metastatic NSCLC: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2012;30(Suppl 15):7514.
   Google Scholar
• Neal JW, Dahlberg SE, Wakelee HA, et al. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol. 2016;17:1661–1671.
   PubMed Web of Science ®Google Scholar
• Belani CP, Yamamoto N, Bondarenko IM, et al. Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small cell lung cancer. BMC Cancer. 2014;14:290.
   PubMed Web of Science ®Google Scholar
• Twelves C, Chmielowska E, Havel L, et al. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small cell lung cancer. Ann Oncol. 2014;25:132–138.
   PubMed Web of Science ®Google Scholar
• Bondarenko IM, Ingrosso A, Bycott P, et al. Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small cell lung cancer. BMC Cancer. 2015;15:339.
   PubMed Web of Science ®Google Scholar
• Goss GD, Arnold A, Shepherd FA, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small cell lung cancer: NCIC Clinical Trials Group BR24 study. J Clin Oncol. 2010;28:49–55.
   PubMed Web of Science ®Google Scholar
• Laurie SA, Solomon BJ, Seymour L, et al. Randomized, double-blind trial of carboplatin and paclitaxel with daily cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. Eur J Cancer. 2014;50:706–712.
   PubMed Web of Science ®Google Scholar
• Dy GK, Mandrekar SJ, Nelson GD, et al. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small cell lung cancer: North central cancer treatment group study N0528. J Thorac Oncol. 2013;8(1):79–88.
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Ruckdeschel JC, Wozniak AJ, et al. Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). J Clin Oncol. 2011;29(Suppl 15):7564.
   Web of Science ®Google Scholar
• Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006;66:8715–8721.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Vynnychenko I, Park K, et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small cell lung cancer: MONET1. J Clin Oncol. 2012;30:2829–2836.
   PubMed Web of Science ®Google Scholar
• Kubota K, Yoshioka H, Oshita F, et al. Phase III, randomized, placebo-controlled, double-blind trial of motesanib (AMG-706) in combination with paclitaxel and carboplatin in East Asian patients with advanced nonsquamous non-small cell lung cancer. J Clin Oncol. 2017;35(32):3662–3670.
   PubMed Web of Science ®Google Scholar
• Tan EH, Goss GD, Salgia R, et al. Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011;6(8):1418–1425.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Shtivelband M, Soo RA, et al. Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small cell lung cancer. J Clin Oncol. 2015;33(5):433–441.
   PubMed Web of Science ®Google Scholar
• Podar K, Tonon G, Sattler M, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A. 2006;103(51):19478–19483.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Burris HA 3rd, Greco FA, et al. Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: a randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures. Cancer. 2018;124(11):2355–2364.
   PubMed Web of Science ®Google Scholar
• Xu JM, Wang Y, Chen YL, et al. Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study. Oncotarget. 2017;8:42076–42086.
   PubMedGoogle Scholar
• Shirley M. Fruquintinib: first global approval. Drugs. 2018;78(16):1757–1761.
   PubMed Web of Science ®Google Scholar
• Westendorf A, Skibbe K, Adamczyk A, et al. Hypoxia enhances immunosuppression by inhibiting CD4+ effector T cell function and promoting Treg activity. Cell Physiol Biochem. 2017;41(4):1271–1284.
   PubMedGoogle Scholar
• Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92(11):4150–4166.
   PubMed Web of Science ®Google Scholar
• Dirkx AEM, Oude Egbrink MGA, Kuijpers MJE, et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions by reducing endothelial adhesion molecule expression. Cancer Res. 2003;63(9):2322–2329.
   PubMed Web of Science ®Google Scholar
• Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15:325.
   PubMed Web of Science ®Google Scholar
• De Bock K. Cauwenberghs S, Carmeliet P. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev. 2011;21(1):73–79.
   PubMed Web of Science ®Google Scholar
• Mauge L, Terme M, Tartour E, et al. Control of the adaptive immune response by tumor vasculature. Front Oncol. 2014;4:61.
   PubMedGoogle Scholar
• Slaney CY, Kershaw MH, Darcy PK. Trafficking of T cells into tumors. Cancer Res. 2014;74(24):7168–7174.
   PubMed Web of Science ®Google Scholar
• Peske JD, Woods AB, Engelhard VH. Control of CD8 T-cell infiltration into tumors by vasculature and microenvironment. Adv Cancer Res. 2015;128:263–307.
   PubMed Web of Science ®Google Scholar
• Lanitis E, Irving M, Coukos G. Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol. 2015;33:55–63.
   PubMed Web of Science ®Google Scholar
• Motz GT, Santoro SP, Wang LP, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607–615.
   PubMed Web of Science ®Google Scholar
• Meder L, Schuldt P, Thelen M, et al. Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer. Cancer Res. 2018;78(15):4270–4281.
   PubMed Web of Science ®Google Scholar
• Yasuda S, Sho M, Yamato I, et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol. 2013;172(3):500–506.
   PubMed Web of Science ®Google Scholar
• Schmittnaegel M, Rigamonti N, Kadioglu E, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med. 2017;9(385):eaak9670.
   PubMed Web of Science ®Google Scholar
• Du Four S, Maenhout SK, Niclou SP, et al. Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs. Am J Cancer Res. 2016;6(11):2514–2531.
   PubMed Web of Science ®Google Scholar
• Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139–148.
   PubMed Web of Science ®Google Scholar
• Ager A. High endothelial venules and other blood vessels: critical regulators of lymphoid organ development and function. Front Immunol. 2017;8:45.
   PubMed Web of Science ®Google Scholar
• Sautès-Fridman C, Lawand M, Giraldo NA, et al. Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. Front Immunol. 2016;7:407.
   PubMed Web of Science ®Google Scholar
• Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781–790.
   PubMed Web of Science ®Google Scholar
• Allen E, Jabouille A, Rivera LB, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;12(385):9.
   Google Scholar
• Varga A, Baldini C, Martin-Roman P, et al. Safety and efficacy results from a phase I dose-escalation trial of nintedanib in combination with pembrolizumab in patients with advanced solid tumors (PEMBIB trial). J Clin Oncol. 2018;36(Suppl 15):3080.
   Web of Science ®Google Scholar
• Conesa-Milián L, Falomir E, Murga J, et al. Novel multitarget inhibitors with antiangiogenic and immunomodulator properties. Eur J Med Chem. 2019;170:87–98.
   PubMed Web of Science ®Google Scholar
• De Luca A, Carotenuto A, Rachiglio A, et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol. 2007;214(3):559–567.
   Web of Science ®Google Scholar
• Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res. 2003;9(4):1546–1556.
   PubMed Web of Science ®Google Scholar
• Natale RB, Bodkin D, Govindan R, et al. Vandetanib versus gefitinib in patients with advanced non-small cell lung cancer: results from a two-part, double-blind, randomized phase II study. J Clin Oncol. 2009;27(15):2523–2529.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011;377(9780):1846–1854.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang H, Shi Y, et al. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small cell lung cancer: a meta-analysis of 16 phase II/III randomized trials. Oncotarget. 2017;8(4):7014–7024.
   PubMedGoogle Scholar
• Hall RD, Le TM, Haggstrom DE, et al. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2015;4(5):515–523.
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: aVAil. J Clin Oncol. 2009;27(8):1227–1234.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small cell lung cancer. J Clin Oncol. 2015;33(19):2197–2204.
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006;355(24):2542–2550.
   PubMed Web of Science ®Google Scholar
• Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomized phase 3 trial. Lancet. 2014;384(9944):665–673.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Adjei AA. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist. 2015;20:660–673.
   PubMed Web of Science ®Google Scholar
• Soria J-C, Mauguen A, Reck M, et al. Systematic review and meta-analysis of randomized, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer. Ann Oncol. 2013;24(1):20–30.
   PubMed Web of Science ®Google Scholar
• Lima ABC, Macedo LT, Sasse AD. Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2011;6(8):e22681.
   PubMed Web of Science ®Google Scholar
• Raphael J, Chan K, Karim S, et al. Antiangiogenic therapy in advanced non-small cell lung cancer: a meta-analysis of phase III randomized trials. Clin Lung Cancer. 2017;18(4):345–353.
   PubMed Web of Science ®Google Scholar
• Potente M, Carmeliet P. The link between angiogenesis and endothelial metabolism. Annu Rev Physiol. 2017;79:43–66.
   PubMed Web of Science ®Google Scholar
• Zecchin A, Kalucka J, Dubois C, et al. How endothelial cells adapt their metabolism to form vessels in tumors. Front Immunol. 2017;8:1750.
   PubMed Web of Science ®Google Scholar
• Manzo A, Montanino A, Carillio G, et al. Angiogenesis inhibitors in NSCLC. Int J Mol Sci. 2017;18(10):e2021.
   PubMed Web of Science ®Google Scholar
• Lung-MAP precision medicine trial expands to include more patients. Lung Cancer Master Protocol. Published January 29, 2019. [cited 2019 Jul 29]. Available from: https://bit.ly/2HD4GLf.
   Google Scholar
• Duignan IJ, Corcoran E, Pennello A, et al. Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models. Neoplasia. 2011;13:49–59.
   PubMed Web of Science ®Google Scholar
• Espinosa Bosch M, Asensi Diez R, García Agudo S, et al. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small cell lung cancer; GENESIS-SEFH drug evaluation report. Farm Hosp. 2016;40(4):316–327.
   PubMedGoogle Scholar
• Hong SD, Fang WF, Liang WH, et al. Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trial. Onco Targets Ther. 2014;7:1851–1867.
   PubMed Web of Science ®Google Scholar
• Wang S, Yang Z, Wang Z. Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer? Oncotarget. 2015;6:18206–18223.
   PubMedGoogle Scholar
• Gu B, Gao WC, Chu HJ, et al. Adverse events risk associated with anti-VEGFR agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. Medicine (Baltimore). 2016;95(48):e3752.
   PubMed Web of Science ®Google Scholar
• Li BT, Barnes TA, Chan DL, et al. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small cell lung cancers: a meta-analysis of randomized trials. Lung Cancer. 2016;102:21–27.
   PubMed Web of Science ®Google Scholar
• Lv WW, Zhang JJ, Zhou XL, et al. Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non-small cell lung cancer: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 2019;98(23):e15806.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang Y, Wei J, et al. VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: a systematic review. J Cancer. 2019;10(4):799–809.
   PubMed Web of Science ®Google Scholar
• Ma W, Xu M, Liu Y, et al. Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small cell lung cancer: a meta-analysis of 15 phase II/III randomized trials. Int J Cancer. 2015;137(2):409–419.
   PubMed Web of Science ®Google Scholar
• Gottfried M, Bennouna J, Bondarenko I, et al. Efficacy and safety of nintedanib plus docetaxel in patients with advanced lung adenocarcinoma: complementary and exploratory analyses of the phase III LUME-Lung 1 study. Target Oncol. 2017;12(4):475–485.
   PubMed Web of Science ®Google Scholar
• Commmitee for Medicinal Products for Human Use (CHMP). European Medicines Agency Assessment report of Opdivo. EMA/246304/2016.
   Google Scholar
• Corral J, Majem M, Rodríguez-Abreu D, et al. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. Clin Transl Oncol. 2019 Feb 15. DOI:10.1007/s12094-019-02053-7.
   Web of Science ®Google Scholar
• Grohé C, Blau W, Gleiber W, et al. Nintedanib plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): preliminary efficacy and safety results of the non-interventional study VARGADO. J Clin Oncol. 2019;37(Suppl 15):9074.
   Web of Science ®Google Scholar